ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcutis Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$31.89+3.07 (+10.65%)
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 145.0
- Dividend yield
- –
Arcutis Biotherapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZORYVE foam | $67.38M | $49.63M | $62.66M | $49.78M | $39.21M | $30.24M | $31.13M | $20.26M | $13.60M | $6.54M | $0 | $0 | 51.9% | +71.8% |
| ZORYVE cream 0.3% | $35.33M | $32.67M | $39.44M | $30.49M | $27.68M | $23.39M | $30.76M | $22.04M | $17.26M | – | $13.53M | $8.11M | 27.2% | +27.6% |
| ZORYVE cream 0.15% | $24.23M | $21.74M | $24.49M | $18.95M | $14.62M | $10.22M | $7.47M | $2.45M | $0 | $0 | $0 | $0 | 18.7% | +65.8% |
| ZORYVE cream 0.05% | $2.93M | $1.36M | – | – | $0 | $0 | – | – | – | – | – | – | 2.3% | – |
| Product revenue, net | – | – | – | – | – | – | – | – | – | – | $13.53M | $8.11M | – | – |
| Other revenue | – | – | – | – | – | – | – | – | – | – | $0 | $30.00M | – | – |
| ZORYVE cream 0.3% | – | – | – | – | – | $23.39M | – | – | $17.26M | $15.03M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Arcutis Biotherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.